Last reviewed 2026-04-22 · How we verify

DAG181

DAG181 is a humanized monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the PD-1/PD-L1 checkpoint inhibition.

DAG181 is a humanized monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the PD-1/PD-L1 checkpoint inhibition. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).

At a glance

Mechanism of action

DAG181 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 on T cells. This blockade restores T cell activation, proliferation, and cytotoxic function, allowing the immune system to recognize and eliminate cancer cells. The mechanism is similar to other PD-L1 checkpoint inhibitors used in oncology.

Approved indications

• Non-small cell lung cancer
• Other solid tumors (under investigation in Phase 3)

Common side effects

• Fatigue
• Decreased appetite
• Immune-related adverse events (pneumonitis, hepatitis, colitis)
• Infusion reactions

Key clinical trials

• Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD (PHASE1)
• To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients (PHASE2)
• A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients (PHASE3)
• Phase 2 Study of Yimitasvir Phosphate Capsules (PHASE2)
• Phase 3 Study of Yimitasvir Phosphate Capsules (PHASE3)
• To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers (PHASE1)
• The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.